Efficacy and Safety of Nimotuzumab in Combination with Radiotherapy or Chemoradiotherapy for Local Advanced Head and Neck Cancer: A Systematic Review and Meta-analysis-Reference-Cited by-同舟云学术

Efficacy and Safety of Nimotuzumab in Combination with Radiotherapy or Chemoradiotherapy for Local Advanced Head and Neck Cancer: A Systematic Review and Meta-analysis

Published:2024-09 Issue:9 Volume:24 Page:952-966
ISSN:1568-0096
Container-title:Current Cancer Drug Targets
language:en
Short-container-title:CCDT

Author:

Zheng Baomin¹^ORCID,He Meilin²^ORCID,Han Yaqian³^ORCID,Jiang Xin⁴^ORCID,Ou Xiaomin⁵^ORCID,Zhang Peng⁶^ORCID,Guo Ruyuan⁷^ORCID,Li Jingao⁸^ORCID,Zhang Ximei⁹^ORCID,Qiao Qiao¹⁰^ORCID,Wu Hui¹¹,Hu Man¹²,Feng Mei¹³,Tu Wenyong¹⁴^ORCID,Yi Junlin²¹⁵^ORCID

Affiliation:

1. Department of Radiation Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Peking University Cancer Hospital & Institute, Beijing, China

2. Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

3. Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China

4. Department of Radiation Oncology, The First Hospital of Jilin University, Changchun, China

5. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China

6. Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, Sichuan, China

7. Deparment of Head and Neck Radiotherapy, Shanxi Tumor Hospital, Taiyuan, Shanxi, China

8. Department of Radiation Oncology, Jiangxi Cancer Hospital, Yichun, Jiangxi, China

9. Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

10. Department of Radiation Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, China

11. Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China

12. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, China

13. Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Chengdu, China

14. Department of Oral and Maxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai, China

15. National Cancer Center/National Clinical Research Center for Cancer, Hebei Cancer Hospital, Chinese Academy of Medical Sciences, Langfang, China

Abstract

Background: The present meta-analysis aimed to evaluate the efficacy and safety of adding nimotuzumab to radiotherapy (RT) or chemoradiotherapy (CRT). Methods: Prospective randomized controlled studies at EMBASE, PubMed, and the Cochrane Library from January 1, 2010, to October 1, 2022, were searched. Data on the overall survival (OS), progress-free survival (PFS), disease-free survival (DFS), complete response rate (CRR), objective response rate (ORR), and all grade adverse events were collected from the enrolled publications. OS was the primary measurement indicator. Pooled analysis was performed with relative risks (RRs), hazard risks (HRs), and their corresponding 95% confidence intervals (CIs) in the software Stata SE 16.0. Results: Six randomized controlled studies were included in the analysis of the overall pooled effect. As compared to the control group, the nimotuzumab intervention group exhibited improved OS by 21% (pooled HR=0.79,95% CI: 0.64-0.98, P=0.028), along with PFS up to 31% (HR=0.69, 95% CI: 0.55-0.86, P=0.001) and DFS up to 29% (HR=0.71, 95% CI: 0.56-0.91, P=0.006), increased CRR as 50% (RR=1.50, 95% CI:1.09-2.04; P=0.012), and ORR as 35% (RR=1.35, 95% CI:1.04-1.73; P=0.022). Regarding safety, nimotuzumab in combination with RT or CRT did not increase the incidence of all grade adverse events (pooled-RD=-1.27, 95% CI:-2.78-0.23, P=0.099). Conclusion: The present meta-analysis has demonstrated that nimotuzumab, in combination with RT or CRT, could provide survival benefits and increase response rates. Its safety profile has been found to be controllable.

Publisher

Bentham Science Publishers Ltd.

Reference51 articles.

1. Fitzmaurice C.; Abate D.; Abbasi N.; Abbastabar H.; Abd-Allah F.; Abdel-Rahman O.; Abdelalim A.; Abdoli A.; Abdollahpour I.; Abdulle A.S.M.; Abebe N.D.; Abraha H.N.; Abu-Raddad L.J.; Abualhasan A.; Adedeji I.A.; Advani S.M.; Afarideh M.; Afshari M.; Aghaali M.; Agius D.; Agrawal S.; Ahmadi A.; Ahmadian E.; Ahmadpour E.; Ahmed M.B.; Akbari M.E.; Akinyemiju T.; Al-Aly Z.; AlAbdulKader A.M.; Alahdab F.; Alam T.; Alamene G.M.; Alemnew B.T.T.; Alene K.A.; Alinia C.; Alipour V.; Aljunid S.M.; Bakeshei F.A.; Almadi M.A.H.; Almasi-Hashiani A.; Alsharif U.; Alsowaidi S.; Alvis-Guzman N.; Amini E.; Amini S.; Amoako Y.A.; Anbari Z.; Anber N.H.; Andrei C.L.; Anjomshoa M.; Ansari F.; Ansariadi A.; Appiah S.C.Y.; Arab-Zozani M.; Arabloo J.; Arefi Z.; Aremu O.; Areri H.A.; Artaman A.; Asayesh H.; Asfaw E.T.; Ashagre A.F.; Assadi R.; Ataeinia B.; Atalay H.T.; Ataro Z.; Atique S.; Ausloos M.; Avila-Burgos L.; Avokpaho E.F.G.A.; Awasthi A.; Awoke N.; Ayala Quintanilla B.P.; Ayanore M.A.; Ayele H.T.; Babaee E.; Bacha U.; Badawi A.; Bagherzadeh M.; Bagli E.; Balakrishnan S.; Balouchi A.; Bärnighausen T.W.; Battista R.J.; Behzadifar M.; Behzadifar M.; Bekele B.B.; Belay Y.B.; Belayneh Y.M.; Berfield K.K.S.; Berhane A.; Bernabe E.; Beuran M.; Bhakta N.; Bhattacharyya K.; Biadgo B.; Bijani A.; Bin Sayeed M.S.; Birungi C.; Bisignano C.; Bitew H.; Bjørge T.; Bleyer A.; Bogale K.A.; Bojia H.A.; Borzì A.M.; Bosetti C.; Bou-Orm I.R.; Brenner H.; Brewer J.D.; Briko A.N.; Briko N.I.; Bustamante-Teixeira M.T.; Butt Z.A.; Carreras G.; Carrero J.J.; Carvalho F.; Castro C.; Castro F.; Catalá-López F.; Cerin E.; Chaiah Y.; Chanie W.F.; Chattu V.K.; Chaturvedi P.; Chauhan N.S.; Chehrazi M.; Chiang P.P.C.; Chichiabellu T.Y.; Chido-Amajuoyi O.G.; Chimed-Ochir O.; Choi J.Y.J.; Christopher D.J.; Chu D.T.; Constantin M.M.; Costa V.M.; Crocetti E.; Crowe C.S.; Curado M.P.; Dahlawi S.M.A.; Damiani G.; Darwish A.H.; Daryani A.; das Neves J.; Demeke F.M.; Demis A.B.; Demissie B.W.; Demoz G.T.; Denova-Gutiérrez E.; Derakhshani A.; Deribe K.S.; Desai R.; Desalegn B.B.; Desta M.; Dey S.; Dharmaratne S.D.; Dhimal M.; Diaz D.; Dinberu M.T.T.; Djalalinia S.; Doku D.T.; Drake T.M.; Dubey M.; Dubljanin E.; Duken E.E.; Ebrahimi H.; Effiong A.; Eftekhari A.; El Sayed I.; Zaki M.E.S.; El-Jaafary S.I.; El-Khatib Z.; Elemineh D.A.; Elkout H.; Ellenbogen R.G.; Elsharkawy A.; Emamian M.H.; Endalew D.A.; Endries A.Y.; Eshrati B.; Fadhil I.; Fallah Omrani V.; Faramarzi M.; Farhangi M.A.; Farioli A.; Farzadfar F.; Fentahun N.; Fernandes E.; Feyissa G.T.; Filip I.; Fischer F.; Fisher J.L.; Force L.M.; Foroutan M.; Freitas M.; Fukumoto T.; Futran N.D.; Gallus S.; Gankpe F.G.; Gayesa R.T.; Gebrehiwot T.T.; Gebremeskel G.G.; Gedefaw G.A.; Gelaw B.K.; Geta B.; Getachew S.; Gezae K.E.; Ghafourifard M.; Ghajar A.; Ghashghaee A.; Gholamian A.; Gill P.S.; Ginindza T.T.G.; Girmay A.; Gizaw M.; Gomez R.S.; Gopalani S.V.; Gorini G.; Goulart B.N.G.; Grada A.; Ribeiro Guerra M.; Guimaraes A.L.S.; Gupta P.C.; Gupta R.; Hadkhale K.; Haj-Mirzaian A.; Haj-Mirzaian A.; Hamadeh R.R.; Hamidi S.; Hanfore L.K.; Haro J.M.; Hasankhani M.; Hasanzadeh A.; Hassen H.Y.; Hay R.J.; Hay S.I.; Henok A.; Henry N.J.; Herteliu C.; Hidru H.D.; Hoang C.L.; Hole M.K.; Hoogar P.; Horita N.; Hosgood H.D.; Hosseini M.; Hosseinzadeh M.; Hostiuc M.; Hostiuc S.; Househ M.; Hussen M.M.; Ileanu B.; Ilic M.D.; Innos K.; Irvani S.S.N.; Iseh K.R.; Islam S.M.S.; Islami F.; Jafari Balalami N.; Jafarinia M.; Jahangiry L.; Jahani M.A.; Jahanmehr N.; Jakovljevic M.; James S.L.; Javanbakht M.; Jayaraman S.; Jee S.H.; Jenabi E.; Jha R.P.; Jonas J.B.; Jonnagaddala J.; Joo T.; Jungari S.B.; Jürisson M.; Kabir A.; Kamangar F.; Karch A.; Karimi N.; Karimian A.; Kasaeian A.; Kasahun G.G.; Kassa B.; Kassa T.D.; Kassaw M.W.; Kaul A.; Keiyoro P.N.; Kelbore A.G.; Kerbo A.A.; Khader Y.S.; Khalilarjmandi M.; Khan E.A.; Khan G.; Khang Y.H.; Khatab K.; Khater A.; Khayamzadeh M.; Khazaee-Pool M.; Khazaei S.; Khoja A.T.; Khosravi M.H.; Khubchandani J.; Kianipour N.; Kim D.; Kim Y.J.; Kisa A.; Kisa S.; Kissimova-Skarbek K.; Komaki H.; Koyanagi A.; Krohn K.J.; Bicer B.K.; Kugbey N.; Kumar V.; Kuupiel D.; La Vecchia C.; Lad D.P.; Lake E.A.; Lakew A.M.; Lal D.K.; Lami F.H.; Lan Q.; Lasrado S.; Lauriola P.; Lazarus J.V.; Leigh J.; Leshargie C.T.; Liao Y.; Limenih M.A.; Listl S.; Lopez A.D.; Lopukhov P.D.; Lunevicius R.; Madadin M.; Magdeldin S.; El Razek H.M.A.; Majeed A.; Maleki A.; Malekzadeh R.; Manafi A.; Manafi N.; Manamo W.A.; Mansourian M.; Mansournia M.A.; Mantovani L.G.; Maroufizadeh S.; Martini S.M.S.; Mashamba-Thompson T.P.; Massenburg B.B.; Maswabi M.T.; Mathur M.R.; McAlinden C.; McKee M.; Meheretu H.A.A.; Mehrotra R.; Mehta V.; Meier T.; Melaku Y.A.; Meles G.G.; Meles H.G.; Melese A.; Melku M.; Memiah P.T.N.; Mendoza W.; Menezes R.G.; Merat S.; Meretoja T.J.; Mestrovic T.; Miazgowski B.; Miazgowski T.; Mihretie K.M.M.; Miller T.R.; Mills E.J.; Mir S.M.; Mirzaei H.; Mirzaei H.R.; Mishra R.; Moazen B.; Mohammad D.K.; Mohammad K.A.; Mohammad Y.; Darwesh A.M.; Mohammadbeigi A.; Mohammadi H.; Mohammadi M.; Mohammadian M.; Mohammadian-Hafshejani A.; Mohammadoo-Khorasani M.; Mohammadpourhodki R.; Mohammed A.S.; Mohammed J.A.; Mohammed S.; Mohebi F.; Mokdad A.H.; Monasta L.; Moodley Y.; Moosazadeh M.; Moossavi M.; Moradi G.; Moradi-Joo M.; Moradi-Lakeh M.; Moradpour F.; Morawska L.; Morgado-da-Costa J.; Morisaki N.; Morrison S.D.; Mosapour A.; Mousavi S.M.; Muche A.A.; Muhammed O.S.S.; Musa J.; Nabhan A.F.; Naderi M.; Nagarajan A.J.; Nagel G.; Nahvijou A.; Naik G.; Najafi F.; Naldi L.; Nam H.S.; Nasiri N.; Nazari J.; Negoi I.; Neupane S.; Newcomb P.A.; Nggada H.A.; Ngunjiri J.W.; Nguyen C.T.; Nikniaz L.; Ningrum D.N.A.; Nirayo Y.L.; Nixon M.R.; Nnaji C.A.; Nojomi M.; Nosratnejad S.; Shiadeh M.N.; Obsa M.S.; Ofori-Asenso R.; Ogbo F.A.; Oh I.H.; Olagunju A.T.; Olagunju T.O.; Oluwasanu M.M.; Omonisi A.E.; Onwujekwe O.E.; Oommen A.M.; Oren E.; Ortega-Altamirano D.D.V.; Ota E.; Otstavnov S.S.; Owolabi M.O.; P A M.; Padubidri J.R.; Pakhale S.; Pakpour A.H.; Pana A.; Park E.K.; Parsian H.; Pashaei T.; Patel S.; Patil S.T.; Pennini A.; Pereira D.M.; Piccinelli C.; Pillay J.D.; Pirestani M.; Pishgar F.; Postma M.J.; Pourjafar H.; Pourmalek F.; Pourshams A.; Prakash S.; Prasad N.; Qorbani M.; Rabiee M.; Rabiee N.; Radfar A.; Rafiei A.; Rahim F.; Rahimi M.; Rahman M.A.; Rajati F.; Rana S.M.; Raoofi S.; Rath G.K.; Rawaf D.L.; Rawaf S.; Reiner R.C.; Renzaho A.M.N.; Rezaei N.; Rezapour A.; Ribeiro A.I.; Ribeiro D.; Ronfani L.; Roro E.M.; Roshandel G.; Rostami A.; Saad R.S.; Sabbagh P.; Sabour S.; Saddik B.; Safiri S.; Sahebkar A.; Salahshoor M.R.; Salehi F.; Salem H.; Salem M.R.; Salimzadeh H.; Salomon J.A.; Samy A.M.; Sanabria J.; Santric Milicevic M.M.; Sartorius B.; Sarveazad A.; Sathian B.; Satpathy M.; Savic M.; Sawhney M.; Sayyah M.; Schneider I.J.C.; Schöttker B.; Sekerija M.; Sepanlou S.G.; Sepehrimanesh M.; Seyedmousavi S.; Shaahmadi F.; Shabaninejad H.; Shahbaz M.; Shaikh M.A.; Shamshirian A.; Shamsizadeh M.; Sharafi H.; Sharafi Z.; Sharif M.; Sharifi A.; Sharifi H.; Sharma R.; Sheikh A.; Shirkoohi R.; Shukla S.R.; Si S.; Siabani S.; Silva D.A.S.; Silveira D.G.A.; Singh A.; Singh J.A.; Sisay S.; Sitas F.; Sobngwi E.; Soofi M.; Soriano J.B.; Stathopoulou V.; Sufiyan M.B.; Tabarés-Seisdedos R.; Tabuchi T.; Takahashi K.; Tamtaji O.R.; Tarawneh M.R.; Tassew S.G.; Taymoori P.; Tehrani-Banihashemi A.; Temsah M.H.; Temsah O.; Tesfay B.E.; Tesfay F.H.; Teshale M.Y.; Tessema G.A.; Thapa S.; Tlaye K.G.; Topor-Madry R.; Tovani-Palone M.R.; Traini E.; Tran B.X.; Tran K.B.; Tsadik A.G.; Ullah I.; Uthman O.A.; Vacante M.; Vaezi M.; Varona Pérez P.; Veisani Y.; Vidale S.; Violante F.S.; Vlassov V.; Vollset S.E.; Vos T.; Vosoughi K.; Vu G.T.; Vujcic I.S.; Wabinga H.; Wachamo T.M.; Wagnew F.S.; Waheed Y.; Weldegebreal F.; Weldesamuel G.T.; Wijeratne T.; Wondafrash D.Z.; Wonde T.E.; Wondmieneh A.B.; Workie H.M.; Yadav R.; Yadegar A.; Yadollahpour A.; Yaseri M.; Yazdi-Feyzabadi V.; Yeshaneh A.; Yimam M.A.; Yimer E.M.; Yisma E.; Yonemoto N.; Younis M.Z.; Yousefi B.; Yousefifard M.; Yu C.; Zabeh E.; Zadnik V.; Moghadam T.Z.; Zaidi Z.; Zamani M.; Zandian H.; Zangeneh A.; Zaki L.; Zendehdel K.; Zenebe Z.M.; Zewale T.A.; Ziapour A.; Zodpey S.; Murray C.J.L.; Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017. JAMA Oncol 2019,5(12),1749-1768

2. Aupérin A.; Epidemiology of head and neck cancers: An update. Curr Opin Oncol 2020,32(3),178-186

3. Wang X.; Hu C.; Application of anti-EGFR monoclonal antibody targeted drugs in the comprehensive treatment of head and neck squamous cell carcinoma. Chin J Cancer [J].2018,28(12),7

4. Pfister D.G.; Spencer S.; Adelstein D.; Adkins D.; Anzai Y.; Brizel D.M.; Bruce J.Y.; Busse P.M.; Caudell J.J.; Cmelak A.J.; Colevas A.D.; Eisele D.W.; Fenton M.; Foote R.L.; Galloway T.; Gillison M.L.; Haddad R.I.; Hicks W.L.; Hitchcock Y.J.; Jimeno A.; Leizman D.; Maghami E.; Mell L.K.; Mittal B.B.; Pinto H.A.; Ridge J.A.; Rocco J.W.; Rodriguez C.P.; Shah J.P.; Weber R.S.; Weinstein G.; Witek M.; Worden F.; Yom S.S.; Zhen W.; Burns J.L.; Darlow S.D.; Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2020,18(7),873-898

5. Grandis J.R.; Melhem M.F.; Gooding W.E.; Day R.; Holst V.A.; Wagener M.M.; Drenning S.D.; Tweardy D.J.; Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998,90(11),824-832